-

Evvy Launches Women’s Complete Probiotic, Delivering Advanced 3-in-1 Microbiome Support for Gut, Urinary, & Vaginal Health

Developed by the scientists behind Evvy’s Vaginal Microbiome Test, the unique formulation offers targeted support for women’s interconnected microbiomes

NEW YORK--(BUSINESS WIRE)--Evvy, the precision women’s health company, today announces the launch of its latest innovation: Evvy Women’s Complete Probiotic. This once-daily supplement delivers advanced 3-in-1 microbiome support for gut, vaginal and urinary health — backed by science and uniquely formulated for women.

Unlike most probiotics that target just one area of health, Evvy Women’s Complete Probiotic is designed to support the full microbiome ecosystem that shapes a woman's wellbeing. The probiotic includes:

  • Clinically-studied Lactobacillus strains to promote healthy bacteria, support yeast balance, and reduce bloating
  • Patented delayed-release capsules that increase survivability of probiotic strains through the GI tract
  • Postbiotics and Vitamins D & E to support immunity and gut barrier integrity

“At Evvy, our research across over 50,000 women has shown just how deeply interconnected the gut, urinary, and vaginal microbiomes are — yet most products continue to treat them in isolation,” said Pita Navarro, Co-founder and Chief Science Officer at Evvy. “That’s why we created a formulation that finally reflects the science: a single research-backed capsule that supports the full picture of women’s microbiome health.”

The launch of the Women’s Complete Probiotic builds on Evvy’s pioneering vaginal healthcare platform, which includes the world’s first at-home Vaginal Microbiome Test powered by metagenomic sequencing, as well as precision prescription treatments. Informed by insights from the largest real-world dataset on the vaginal microbiome, Evvy Women’s Complete Probiotic is designed as a proactive daily essential for supporting gut, urinary, and vaginal health.

The Women’s Complete Probiotic is available for $55 for a monthly supply of 30 capsules or $44/month with a subscription. To learn more visit, evvy.com/womens-complete-probiotic.

About Evvy:

Founded in 2021, Evvy is closing the gender health gap by leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company offers the world’s first Vaginal Microbiome Test powered by metagenomic sequencing, analyzing over 700 microbes with a single, at-home swab — including those related to bacterial vaginosis, yeast infections, fertility outcomes, and more. Evvy’s care platform also includes precision treatment pathways from licensed clinicians and 1:1 health coaching. Through their test and care platform, Evvy has built the world’s largest dataset on the vaginal microbiome, and they are leveraging this novel data to improve outcomes across women’s health.

Contacts

Media Contact:
Jess Bryant
SolComms
evvy@solcomms.co

Evvy


Release Versions

Contacts

Media Contact:
Jess Bryant
SolComms
evvy@solcomms.co

More News From Evvy

Evvy Deepens Its Commitment to Menopause Care with Precision Treatments for Midlife Vaginal Health

NEW YORK--(BUSINESS WIRE)--Evvy, the vaginal microbiome company pioneering biomarker-driven women’s healthcare, today announced the launch of a new Estradiol Vaginal Cream — uniquely formulated without parabens or sulfates. The Estradiol Vaginal Cream is offered alongside Evvy’s Vaginal Health Test and Clinical Care platform, enabling a first-of-its-kind, personalized, and holistic approach to vaginal changes in menopause. Together, the test and treatments enable personalized insights and ongoi...

Evvy Surpasses 75,000 Patients, Marking a New Era of Momentum in Vaginal Microbiome-Driven Care

NEW YORK--(BUSINESS WIRE)--Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and new data highlighting the impact of their platform. Evvy now supports over 75,000 patients and 2,000 healthcare providers with its leading vaginal microbiome testing and care platform. Vaginal discomfort is a leading reason women seek healthcare, and the standard of care leaves women with unacceptably high misdiagnosis (>60%) an...

Evvy Launches Male Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

NEW YORK--(BUSINESS WIRE)--Evvy, the pioneering vaginal healthcare platform, today announces the launch of its Male Partner BV Treatment, a research-backed, two-part antibiotic regimen designed to help reduce bacterial vaginosis (BV) recurrence in women by treating their male partners. BV is the most common vaginal infection in women of reproductive age, with over half of those treated experiencing recurrence within six months. Yet, care has long focused on women, ignoring a critical piece of t...
Back to Newsroom